Jun 24, 2025 07:38AM BriaCell Therapeutics (BCTX) Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

May 27, 2025 07:31AM BriaCell Therapeutics' (BCTX) Bria-OTS Phase 1/2 Study Clears Safety Evaluation

May 23, 2025 07:42AM BriaCell Therapeutics (BCTX) Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

Apr 24, 2025 07:32AM BriaCell Therapeutics (BCTX) Confirms 100% Resolution of Lung Metastasis with Bria-OTS

Apr 22, 2025 07:31AM BriaCell Therapeutics (BCTX) Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer

Apr 16, 2025 07:31AM BriaCell Therapeutics (BCTX) Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 20, 2025 08:02AM BriaCell Therapeutics (BCTX) Reports Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study

Feb 3, 2025 04:45PM BriaCell Therapeutics (BCTX) Announces Proposed Public Offering of Common Shares

Dec 11, 2024 04:05PM BriaCell Therapeutics (BCTX) Announces Proposed Share Offering

Dec 2, 2024 07:50AM BriaCell Therapeutics (BCTX) Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

Oct 15, 2024 07:51AM BriaCell Therapeutics (BCTX) Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Study

Oct 1, 2024 02:05PM BriaCell Therapeutics (BCTX) Announces $5 Million Offering

Sep 11, 2024 12:10PM BriaCell Therapeutics (BCTX) Announces $8.5 Million Offering of Common Shares, Warrants

Sep 10, 2024 07:51AM BriaCell Therapeutics (BCTX) Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer

Jul 18, 2024 07:57AM BriaCell Therapeutics (BCTX) Quadruples Progression Free Survival in Patient with “Eye-Bulging” Metastatic Breast Cancer